Literature DB >> 19732305

Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome.

Sandra Filippi1, Linda Vignozzi, Annamaria Morelli, Aravinda K Chavalmane, Erica Sarchielli, Benedetta Fibbi, Farid Saad, Peter Sandner, Peggy Ruggiano, Gabriella B Vannelli, Edoardo Mannucci, Mario Maggi.   

Abstract

INTRODUCTION: Metabolic syndrome (MetS) is a clustering of cardio-metabolic risk factors (hyperglycemia, hypertension, dyslipidemia, visceral fat accumulation) that is also associated with hypogonadism and erectile dysfunction (ED). AIM: To clarify the relationships among MetS, hypogonadism, and ED, we developed an animal model of MetS.
METHODS: Male rabbits fed a high-fat diet (HFD), with or without testosterone (T) supplementation, were compared with control rabbits (fed a standard chow) and with rabbits made hypogonadal by a single injection of a long-acting GnRH-analog, triptorelin. MAIN OUTCOME MEASURES: Evaluation of metabolic disturbances (plasma glucose, cholesterol, triglycerides, testosterone, LH, FSH level, glucose tolerance, mean arterial pressure, visceral fat accumulation), and corpora cavernosa (CC) relaxant capacity (in vitro contractility study) in HFD animals as compared with control, GnRH analog-treated rabbits, and T-supplemented HFD rabbits.
RESULTS: HFD rabbits showed all the features of MetS. HFD induced hypogonadotropic hypogonadism is characterized by a reduction of plasma T, FSH, LH levels, testis and seminal vesicles weight, and testicular steroidogenic enzymes. Such a phenotype is similar to that induced by triptorelin administration. A reduced GnRH immunopositivity in hypothalamus suggests a central origin of HFD-related hypogonadism. HFD also induced penile alterations, as demonstrated by a reduction of acetylcholine-and electrical field stimulation-induced CC relaxation, hyper-responsiveness to the NO donor, SNP, and unresponsiveness to PDE5 inhibitors. Similar penile alterations were observed in triptorelin treated rabbit. In HFD, as well as in triptorelin treated rabbits, PDE5 and eNOS mRNA expression quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) were significantly decreased. T administration prevented almost all penile alterations observed in HFD rabbits. T treatment dramatically reduced HFD-induced visceral obesity, partially ameliorating also the metabolic profile.
CONCLUSION: We have developed an animal model of MetS associated with hypogonadotropic hypogonadism and penile alterations including unresponsiveness to PDE5 inhibitors. T supplementation was able to partially revert HFD-induced phenotype.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19732305     DOI: 10.1111/j.1743-6109.2009.01467.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  38 in total

1.  An Experimental Model of Diet-Induced Metabolic Syndrome in Rabbit: Methodological Considerations, Development, and Assessment.

Authors:  Óscar Julián Arias-Mutis; Patricia Genovés; Conrado J Calvo; Ana Díaz; Germán Parra; Luis Such-Miquel; Luis Such; Antonio Alberola; Francisco Javier Chorro; Manuel Zarzoso
Journal:  J Vis Exp       Date:  2018-04-20       Impact factor: 1.355

Review 2.  Benign prostatic hyperplasia: a new metabolic disease?

Authors:  L Vignozzi; G Rastrelli; G Corona; M Gacci; G Forti; M Maggi
Journal:  J Endocrinol Invest       Date:  2014-01-24       Impact factor: 4.256

Review 3.  Hypogonadism and metabolic syndrome.

Authors:  G Corona; G Rastrelli; A Morelli; L Vignozzi; E Mannucci; M Maggi
Journal:  J Endocrinol Invest       Date:  2011-06-27       Impact factor: 4.256

Review 4.  Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome.

Authors:  Linda Vignozzi; Mauro Gacci; Mario Maggi
Journal:  Nat Rev Urol       Date:  2016-01-12       Impact factor: 14.432

Review 5.  Management of benign prostatic hyperplasia: role of phosphodiesterase-5 inhibitors.

Authors:  M Gacci; M Carini; M Salvi; A Sebastianelli; L Vignozzi; G Corona; M Maggi; K T McVary; S A Kaplan; M Oelke; S Serni
Journal:  Drugs Aging       Date:  2014-06       Impact factor: 3.923

Review 6.  Translational Perspective on the Role of Testosterone in Sexual Function and Dysfunction.

Authors:  Carol A Podlasek; John Mulhall; Kelvin Davies; Christopher J Wingard; Johanna L Hannan; Trinity J Bivalacqua; Biljana Musicki; Mohit Khera; Nestor F González-Cadavid; Arthur L Burnett
Journal:  J Sex Med       Date:  2016-08       Impact factor: 3.802

Review 7.  The role of testosterone in erectile dysfunction.

Authors:  Giovanni Corona; Mario Maggi
Journal:  Nat Rev Urol       Date:  2009-12-08       Impact factor: 14.432

Review 8.  Sexual function in men undergoing androgen deprivation therapy.

Authors:  G Corona; S Filippi; P Comelio; N Bianchi; F Frizza; M Dicuio; G Rastrelli; S Concetti; A Sforza; L Vignozzi; M Maggi
Journal:  Int J Impot Res       Date:  2021-03-21       Impact factor: 2.896

9.  Improvement of erectile function by Korean red ginseng (Panax ginseng) in a male rat model of metabolic syndrome.

Authors:  Sung-Dae Kim; Young-Joo Kim; Jung-Sik Huh; Sae-Woong Kim; Dong-Wan Sohn
Journal:  Asian J Androl       Date:  2013-02-04       Impact factor: 3.285

Review 10.  Erectile dysfunction.

Authors:  Faysal A Yafi; Lawrence Jenkins; Maarten Albersen; Giovanni Corona; Andrea M Isidori; Shari Goldfarb; Mario Maggi; Christian J Nelson; Sharon Parish; Andrea Salonia; Ronny Tan; John P Mulhall; Wayne J G Hellstrom
Journal:  Nat Rev Dis Primers       Date:  2016-02-04       Impact factor: 52.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.